LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which  include naturally occuring cells to restore function.

Living Cell Technologies was initially formed to commercialise research into treatments for type 1 diabetes. Today we are a recognised world leader in pioneering cell transplant therapeutics.

LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

Living Cell Technologies is developing cell therapies for neurodegenerative diseases with high unmet clinical need.

DIABECELL^® is a breakthrough cell therapy that has the potential to change the lives of the millions of people worldwide with type 1 diabetes.
 

Type 1 diabetes arises from the failure of the pancreas to produce insulin, the hormone required to control glucose uptake by cells in the body.  It results from the body destroying its own insulin producing cells in the pancreas.  It generally develops during childhood and is also referred to as juvenile diabetes or insulin dependent diabetes mellitus. Type 1 diabetes usually requires life-long treatment with regular insulin injections.
 

Parkinson’s disease is a progressive neurological condition characterised by a loss of brain cells that produce dopamine (a neurotransmitter that conveys messages between brain cells to ensure effective movement and planning of movement) and many other types of neurons. People with Parkinson’s disease experience reduced and slow movement (hypokinesia and bradykinesia), rigidity and tremors.

NTCELL^®, a unique cell therapy, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring “support” cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with LCT’s propriety technology IMMUPEL™ to protect them from attack by the immune system. Therefore, no immunosuppressive regimen is required for treatment.

The target product profile for DIABECELL^® is clinically significant reduction of serious recurrent hypoglycaemia (low blood glucose levels) or recurrent hyperglycaemia (high blood glucose levels) or unaware hypoglycaemia resulting in clinically significant improvement in metabolic control in people with type 1 diabetes and poor blood glucose control.
 

DIABECELL^® is currently in late-stage clinical trials.
 

NTCELL^® is expected to be indicated for restoration of function and slowing of disease progression in younger patients with early stage Parkinson’s disease experiencing reduced response to standard medical therapy – any one of the following:
                                -  "On" time characterised by dyskinesias (or other non-motor side effects)
                                -  "Off" time characterised by tremor, rigidity, or akinesia/bradykinesia.
                                -  "On/Off" motor fluctuations. 

LCT commenced a Phase IIb study in March 2016. The study aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. The study is being led by Dr. Barry Snow at Auckland City Hospital. 

In May 2019 the 24 month efficacy data for all three dose groups will be available. At each data milestone we review the findings with our NTCELL medical advisory board to determine the next appropriate steps.

LCT is developing new products in line with its mission to improve the well-being of people with serious diseases worldwide by discovering, developing and commercialising breakthrough treatments which include naturally occurring cells to restore function. 

LCT actively protects a range of intellectual property consisting in our core transplantation and encapsulation technologies, our indication specific therapeutics and the use of designated pathogen free cells from a herd of Auckland Island pigs.

test

There are currently no vacancies at Living Cell Technologies.

We’re interested to hear from smart people who would like to join our team. Please contact us at: careers@lctglobal.com.

Mission

Our breakthrough encapsulation delivery technology, IMMUPEL™, is available for license. We will process your live cells in our GMP facility for your research program, enabling your therapy to be delivered without immunosuppression.